Drug Search Results
More Filters [+]


Alternative Names: zaleplon, sonata, skp-1041
Latest Update: 2024-07-09
Latest Update Note: News Article

Product Description

Zaleplon is a pyrazolopyrimidine hypnotic agent which is indicated for the short term (2 to 4 weeks) management of insomnia. Zaleplon 5 and 10 mg at bedtime (usual recommended doses) significantly reduced sleep latency compared with placebo in clinical trials in nonelderly and elderly patients with insomnia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10983740/)

Mechanisms of Action: GABA Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Egypt | European Medicines Agency | Germany | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Lithuania | New Zealand | Peru | Poland | Portugal | Romania | Russia | Sweden | Taiwan | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zaleplon

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events